Gibson Caitlin M, Finks Shannon W
University of North Texas System College of Pharmacy, Fort Worth.
University of Tennessee College of Pharmacy, Memphis.
Am J Med. 2017 Aug;130(8):900-906. doi: 10.1016/j.amjmed.2017.02.048. Epub 2017 Apr 6.
Edoxaban is the most recently approved factor Xa inhibitor within the class of direct oral anticoagulants (DOACs). Like other DOACs, edoxaban was approved by the US Food and Drug Administration for treatment of venous thromboembolism and prevention of stroke in patients with nonvalvular atrial fibrillation. Similar to other DOACs, edoxaban has fewer drug-drug interactions than warfarin and does not require routine laboratory monitoring. Unlike other DOACs, edoxaban has yet to be approved for secondary or postoperative venous thromboembolism thromboprophylaxis. Currently no antidote for edoxaban is available. To optimally prescribe agents in the DOAC class, it is critical that providers 1) understand how the agents compare; and 2) identify specific settings in which one agent may be preferred over another.
依度沙班是直接口服抗凝剂（DOACs）类别中最近获批的Xa因子抑制剂。与其他DOACs一样，依度沙班被美国食品药品监督管理局批准用于治疗静脉血栓栓塞症以及预防非瓣膜性心房颤动患者的中风。与其他DOACs相似，依度沙班与华法林相比药物相互作用更少，且无需常规实验室监测。与其他DOACs不同的是，依度沙班尚未被批准用于继发性或术后静脉血栓栓塞症的血栓预防。目前尚无依度沙班的解毒剂。为了以最佳方式开具DOAC类药物，医疗服务提供者必须做到：1）了解这些药物之间的比较情况；2）确定在哪些特定情况下一种药物可能比另一种更受青睐。
